Seroprevalence of pandemic A(H1N1) pmd09 virus antibodies in Mexican health care workers before and after vaccination

Archives of Medical Research

Volumn 46, Issue 2, 2015, Pages 154-163

  Aguilar Madrid, Guadalupe ^a   Castelán Vega, Juan Arturo ^b   Juárez Pérez, Cuauhtémoc Arturo ^a   Ribas Aparicio, Rosa María ^b   Estrada García, Iris ^b   Baltierra Jasso, Laura ^b   Cervantes Servín, Nicté ^a   Méndez Ortega, Vanessa ^b   Haro García, Luis C ^c   Sánchez Román, Francisco Raúl ^a   Ortiz Navarrete, Vianney ^d   Fabila Castillo, Luis H ^b   Magaña Hernández, Anastasia ^b   Chávez Negrete, Adolfo ^e   Salamanca Gómez, Fabio Abdel ^a   Jiménez Alberto, Alicia ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE LA CIUDAD DE MÉXICO   (Mexico)

^d DEPARTAMENTO DE FÍSICA   (Mexico)

^e HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Health care workers; Influenza A(H1N1)pdm09; Retroviral pseudotypes; Seroprevalence; Vaccination

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD BANK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SURVEILLANCE; FEMALE; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MEXICAN; MODEL; NURSE; OCCUPATIONAL EXPOSURE; RESIDENT; SEROPREVALENCE; VACCINATION; VIRUS NEUTRALIZATION; YOUNG ADULT; BLOOD; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MEXICO; MIDDLE AGED; PHYSICIAN; QUESTIONNAIRE; STATISTICAL MODEL;

ADULT; AGED; ANTIBODIES, VIRAL; BLOOD BANKS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH PERSONNEL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MEXICO; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PHYSICIANS; SEROEPIDEMIOLOGIC STUDIES; SURVEYS AND QUESTIONNAIRES; VACCINATION; YOUNG ADULT;

EID: 84928746781     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2015.03.001     Document Type: Article

References (31)

1. World Health Organization (WHO). World now at the start of 2009 influenza pandemic. (accessed March 9, 2012). http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html.
2. Marzoratti L., Iannella H.A., Gómez V.F., et al. Recent advances in the diagnosis and treatment of influenza pneumonia. Curr Infect Dis Rep 2012, 14:275-283.
3. Elementos Técnicos Considerados en la Valuación Actuarial del Pasivo Laboral del Instituto y en el Estudio Actuarial de la Subcuenta 2 delFondo Laboral. Available online at: and (accessed August 9, 2012). http://www.imss.gob.mx/estadisticas/financieras/Documents/vaRJP31dic2009.pdf.
4. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR) 2010, 59:1-5. Centers for Disease Control and Prevention.
5. Sanofi Pasteur. 449/454 Influenza A (H1N1) 2009 Monovalent Vaccine. (accessed August 9, 2012). http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182404.pdf.
6. Wang W., Butler E.N., Veguilla V., et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. JVirol Methods 2008, 153:111-119.
7. Hung I.F., To K.K., Lee C.K., et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010, 51:274-279.
8. Moreno-Altamirano A., López-Moreno S., Hernández-Ávila M. Principales Medidas en Epidemiología, Diseño y Análisis de Estudios 2007, 33-60. Editorial Panamericana, Mexico City.
9. La Torre G., Mannocci A., Ursillo P., et al. Prevalence of influenza vaccination among nurses and ancillary workers in Italy: systematic review and meta-analysis. Hum Vaccines 2011, 7:728-733.
10. Amodio E., Anastasi G., Marsala M.G., et al. Vaccination against the 2009 pandemic influenza A(H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy). Vaccine 2011, 29:1408-1412.
11. Centers for Disease Control and Prevention (CDC). Final estimates for2009-10 Seasonal Influenza and Influenza A(H1N1) 2009 MonovalentVaccination Coverage-United States, August 2009-May 2010. (accessed August 9, 2012). http://www.cdc.gov/flu/professionals/vaccination/coverage_0910estimates.htm.
12. Apisarnthanarak A., Mundy L.M. Factors associated with health care-associated 2009 influenza A(H1N1) virus infection among Thai health care workers. Clin Infect Dis 2010, 51:368-369.
13. Bandaranayake D., Jacobs M., Baker M., et al. The second wave of 2009 pandemic influenza A(H1N1) in New Zealand, January-October 2010. Euro Surveill 2011, 16.
14. Chan Y.J., Lee C.L., Hwang S.J., et al. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. J Chin Med Assoc 2010, 73:62-66.
15. Lee V.J., Tan C.H., Yap J., et al. Effectiveness of pandemic H1N1-2009 vaccination in reducing laboratory confirmed influenza infections among military recruits in tropical Singapore. PLoS One 2011, 6:e26572.
16. Olalla J., Marcos M., Fernández F., et al. Screening for pandemic (H1N1) 2009 virus among hospital staff, Spain. Emerg Infect Dis 2011, 17:1139-1140.
17. Smith K., Warner P., Williams L.J., et al. Prevalence of influenza A(H1N1) seropositivity in unvaccinated healthcare workers in Scotland at the height of the global pandemic. J Environ Public Health 2011, 2011:407505.
18. Tandale B.V., Pawar S.D., Gurav Y.K., et al. Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India. BMC Infect Dis 2010, 10:255.
19. Xu C., Bai T., Iuliano A.D., et al. The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS One 2011, 6:e17919.
20. Yang P., Zhang L., Shi W., et al. Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of 2010/2011 influenza vaccine during 2010/2011 season in Beijing, China. Influenza Other Respir Viruses 2012, 6:381-388.
21. Deng Y., Pang X.H., Yang P., et al. Serological survey of 2009 H1N1 influenza in residents of Beijing, China. Epidemiol Infect 2011, 139:52-58.
22. McVernon J., Laurie K., Nolan T., et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October-December 2009. Euro Surveill 2010, 15.
23. Secretaría de Salud, Instituto de Diagnóstico y Referencia Epidemiológicos (INDRE). Available at: (accessed August 9, 2012). http://www.cenavece.salud.gob.mx/epidemiologia/index.html.
24. Hsieh Y.H., Ma S., Velasco-Hernández J.X., et al. Early outbreak of 2009 influenza A (H1N1) in Mexico prior to identification of pH1N1 virus. PLoS One 2011, 6:e23853.
25. Boletín Epidemiológico Semanal. Available at: (accessed August 9, 2012). http://portal.ssa.gob.mx/.
26. Información para el levantamiento de la alerta epidemiológica de influenza A(H1N1). and (accessed August 9, 2012). http://portal.salud.gob.mx/descargas/pdf/influenza/situacion_actual_epidemia_300709.pdf.
27. Alberini I., Tordello E.D., Fasolo A., et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009, 27:5998-6003.
28. Manual for the laboratory diagnosis and virological surveillance of influenza 2011, World Health Organization (WHO) Global Influenza Surveillance Network, WHO Press, Geneva.
29. Temperton N., Hoschler K., Major D., et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses 2007, 1:105-112.
30. Garcia J., Lagardea N., Mab E.S.K., et al. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J Clin Virol 2010, 47:29-33.
31. Petric M., Comanor L., Petti C.A. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis 2006, 194(suppl 2):S98-S110.